Commentary - EC final report: bark worse than bite?
This article was originally published in Scrip
Executive Summary
On July 8th, 2009, the European Commission reported on its 18-month inquiry into competition in the pharmaceuticals sector. Bill Batchelor of Baker & McKenzie's Brussels antitrust practice describes some of the implications of the much-awaited report.
You may also be interested in...
New EU Strategy Targets Pharma Supply, Affordability & Innovation
A new pharmaceutical strategy is to be published later this year aimed at ensuring the availability and the supply of medicines.
European Court Judgment Changes the Rules for Dominant Companies
Bill Batchelor highlights the far-reaching implications of the AstraZeneca judgment.
AstraZeneca judgement changes the rules for dominant companies
On 1 July 2010 the EU General Court handed down its judgement in the long-running saga of AstraZeneca's proton pump inhibitor anti-ulcer product Losec (omeprazole). Although dealing with events that happened almost two decades ago, the case – barring appeal – is set to cast a long shadow over the activities of patent and regulatory professionals.